APA (7th ed.) Citation

V, J., K, S., J, S., N, S., M, M., D, R., & M, C. (2021). Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: Predicting survival and toxicity. Expert review of anticancer therapy, 21(6), 673. https://doi.org/10.1080/14737140.2021.1893694

Chicago Style (17th ed.) Citation

V, Jokic, Savic-Vujovic K, Spasic J, Stanic N, Marinkovic M, Radosavljevic D, and Cavic M. "Hematological Parameters in EGFR-mutated Advanced NSCLC Patients Treated with TKIs: Predicting Survival and Toxicity." Expert Review of Anticancer Therapy 21, no. 6 (2021): 673. https://doi.org/10.1080/14737140.2021.1893694.

MLA (9th ed.) Citation

V, Jokic, et al. "Hematological Parameters in EGFR-mutated Advanced NSCLC Patients Treated with TKIs: Predicting Survival and Toxicity." Expert Review of Anticancer Therapy, vol. 21, no. 6, 2021, p. 673, https://doi.org/10.1080/14737140.2021.1893694.